Paul Bisaro - Zoetis Independent Director

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:3em;padding-top: 38px;;'>ZTS</div>
ZTS -- USA Stock  

Report: 6th of August 2020  

  Director
Mr. Paul M. Bisaro is Independent Director of the Company. Mr. Bisaro was the Executive Chairman of the board of directors of Allergan plc from July 2014 to October 2016. Until June 2014, Mr. Bisaro formerly served as President and Chief Executive Officer from March 2017 to May 2018. Mr. Bisaro was the Executive Chairman of the board of directors of Allergan plc from July 2014 to October 2016. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis, a global pharmaceutical company . He was appointed President, Chief Executive Officer and a member of the board of Watson Pharmaceuticals in September 2007 and was later appointed Chairman of the board of Watson Pharmaceuticals in October 2013. Prior to joining Watson, Mr. Bisaro was President, Chief Operating Officer and a member of the board of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company, from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999 served in various additional capacities including Senior Vice President Strategic Business Development. Prior to joining Barr, Mr. Bisaro was associated with the law firm Winston Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. Mr. Bisaro currently serves on the Board of Visitors of The Catholic University of Americas Columbus School of Law. Mr. Bisaro previously served on the boards of Allergan plc from 2007 to 2018 and Zimmer Biomet Holdings, Inc., a world leader in musculoskeletal health solutions, from 2013 to 2017. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C. Mr. Bisaros business, management and leadership experience, his understanding of the pharmaceutical industry, and his public company board experience make him a valuable member of our Board.
Age: 58  Director Since 2015      
973 822-7000  www.zoetis.com
Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C.

Paul Bisaro Latest Insider Activity

Zoetis Management Efficiency

Zoetis Inc has Return on Asset of 12.48 % which means that on every $100 spent on asset it made $12.48 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 63.55 %, implying that it generated $63.55 on every 100 dollars invested. Zoetis management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. As of 07/13/2020, Return on Sales is likely to grow to 0.28, while Return on Investment is likely to drop 19.96. Zoetis Tax Assets are relatively stable at the moment as compared to the past year. Zoetis reported last year Tax Assets of 110.4 Million. As of 07/13/2020, Revenue to Assets is likely to grow to 0.66, while Current Assets are likely to drop slightly above 4 B. Zoetis Total Liabilities is relatively stable at the moment as compared to the past year. Zoetis reported last year Total Liabilities of 8.84 Billion. As of 07/13/2020, Tax Liabilities is likely to grow to about 470.9 M, while Current Liabilities is likely to drop slightly above 1.5 B.
The company has 6.69 B in debt with debt to equity (D/E) ratio of 2.43, meaning that the company heavily relies on borrowing funds for operations. Zoetis Inc has a current ratio of 2.71, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

James SmithPfizer Inc
2014
James KiltsPfizer Inc
2007
Anthony ColesRegeneron Pharmaceuticals
2017
Patrick OSullivanAllergan Plc
2013
Bonnie BasslerRegeneron Pharmaceuticals
2016
Stephen SangerPfizer Inc
2009
Dan LittmanPfizer Inc
2018
David GreenwayVertex Pharmaceuticals Incorpor
2017
Charles BakerRegeneron Pharmaceuticals
N/A
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Leo PuriDr Reddys Laboratories
2018
Theodore SamuelstoPerrigo Company Plc
2017
Donal OConnorPerrigo Company Plc
2014
Ravi BhoothalingamDr Reddys Laboratories
2000
Michael GallagherAllergan Plc
2015
Shlomo YanaiPerrigo Company Plc
N/A
Shantanu NarayenPfizer Inc
2019
Suzanne JohnsonPfizer Inc
2007
Kalpana MorpariaDr Reddys Laboratories
2007
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Ron TaylorAllergan Plc
2013

Company Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on BATS Exchange. It employs 10600 people.Zoetis Inc (ZTS) is traded on BATS Exchange in USA and employs 10,600 people.

Zoetis Inc Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director
William Steere, Independent Director
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Current Sentiment - ZTS

Zoetis Inc Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis Inc. What is your take regarding investing in Zoetis Inc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.7em;padding-top:4px;;'>S</div>
Sold over 300 shares of
six days ago
Traded for 8.62
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>GM</div>
Sold over 100 shares of
six days ago
Traded for 25.24
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:0.9em;padding-top: 12px;;'>XOM</div>
Sold over 60 shares of
six days ago
Traded for 44.08
Check out Your Current Watchlist. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page